Efficacy and safety of intravenous golimumab plus methotrexate in patients with rheumatoid arthritis aged < 65 years and those ≥ 65 years of age. [electronic resource]
Producer: 20200826Description: 190 p. digitalISSN:- 1478-6362
- Age Factors
- Aged
- Antibodies, Monoclonal -- administration & dosage
- Antirheumatic Agents -- administration & dosage
- Arthritis, Rheumatoid -- diagnosis
- Disease Progression
- Dose-Response Relationship, Drug
- Double-Blind Method
- Drug Therapy, Combination
- Female
- Humans
- Infusions, Intravenous
- Male
- Methotrexate -- administration & dosage
- Middle Aged
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.